Applying Process Analytical Technology to Biotech Unit Operations - - BioPharm International

ADVERTISEMENT

Applying Process Analytical Technology to Biotech Unit Operations


BioPharm International
Volume 19, Issue 8


Table 3. Estimations of recovery from the JMP model for a given load purity and to get a targeted pool purity of 94% (mAU = milli absorbance unit).
The proposed scheme requires that the manufacturing operators be trained to interpret and act upon the data from the HPLC. Further, since the pooling decision to end the refold is based on HPLC data, it is critical that the analytical methods have the required robustness. It may be necessary to have redundancy (e.g., duplicate analysis) built into the control scheme to ensure accuracy of the data. Since the aim is to achieve consistent pool purity by shifting stop collect criteria, recovery across the chromatographic step is expected to vary from lot to lot. It is seen in Table 3 that when load purity drops from 86% to 78% and the target for pool purity is 94%, column recovery decreases from 99% to 95%.

Implementation of a PAT-based control scheme for a process chromatography step is feasible and will offer several benefits. This would be particularly attractive when a high-performance separation is being accomplished. Then a purity-based pooling criterion will allow for a dynamic control scheme that can yield consistent pool purity.

CONCLUSION

For the three unit operations that were examined in this article, we have shown that it is feasible to design control schemes that rely on measuring product quality attributes. We project gains in consistency and operational efficiencies. However, these schemes require highly trained operators to deal with complexity. There is likely to be increased variability in step recovery, a parameter that is commonly considered as an indicator of process consistency. It is evident that adoption of control schemes such as these presented here will require changes in our approaches toward process and analytical development, manufacturing, quality assurance, and regulatory filings.

ACKNOWLEDGMENTS

The authors would like to thank Duane Bonham and Duncan Low of Amgen for useful discussions.

Anurag S. Rathore, PhD, is associate director of process development at Amgen Inc., 30W-2-A; One Amgen Center Drive, Thousand Oaks, CA 91320, 805.447.4491, fax 805.499.5008,

Ashutosh Sharma and David Chilin are process development engineers at Amgen Inc.
Anurag Rathore is a member of the Editorial Advisory Board.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here